Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma

Overview

Journal Ann Dermatol

Specialty Dermatology

Date 2021 Apr 29

PMID 33911569

Authors

Jiyoung Rhee

Jaemin Jo

Sang-Hoon Han

Jung-Mi Kwon

Affiliations

Soon will be listed here.

Abstract

No effective systemic chemotherapy is well-established in basal cell carcinoma. We report a case with three simultaneous malignancies: colon cancer, basal cell carcinoma, and smoldering multiple myeloma. The patient was treated with capecitabine and oxaliplatin after surgery for colon cancer. Surprisingly, he achieved a complete response for basal cell carcinoma. This is the first report of this chemotherapy regimen in basal cell carcinoma. This finding suggests that combination capecitabine and oxaliplatin can be a treatment option for patients unable to receive local therapy.

References

Ganti A, Kessinger A . Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. Cancer Treat Rev. 2011; 37(6):440-3. DOI: 10.1016/j.ctrv.2010.12.002. View

Cirrone F, Harris C . Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012; 34(10):2039-50. DOI: 10.1016/j.clinthera.2012.08.011. View

Oh C, Cho H, Won Y, Kong H, Roh Y, Jeong K . Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea. Cancer Res Treat. 2017; 50(3):729-737. PMC: 6056982. DOI: 10.4143/crt.2017.166. View

Endrizzi B, Lee P . Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg. 2009; 35(10):1567-72. DOI: 10.1111/j.1524-4725.2009.01277.x. View

Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee P, Dudek A . Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2010; 25(4):541-8. DOI: 10.1111/j.1399-0012.2010.01348.x. View

Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R . Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol. 2017; 28(8):1738-1750. PMC: 5834015. DOI: 10.1093/annonc/mdx110. View

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

Moeholt K, Aagaard H, Pfeiffer P, Hansen O . Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. Acta Oncol. 1996; 35(6):677-82. DOI: 10.3109/02841869609083998. View

Rubin A, Chen E, Ratner D . Basal-cell carcinoma. N Engl J Med. 2005; 353(21):2262-9. DOI: 10.1056/NEJMra044151. View

10.

Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J . Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23):2171-9. PMC: 5278761. DOI: 10.1056/NEJMoa1113713. View

11.

Poggi L, Kolesar J . Vismodegib for the treatment of basal cell skin cancer. Am J Health Syst Pharm. 2013; 70(12):1033-8. DOI: 10.2146/ajhp120311. View

12.

Arkenau H, Arnold D, Cassidy J, Diaz-Rubio E, Douillard J, Hochster H . Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008; 26(36):5910-7. DOI: 10.1200/JCO.2008.16.7759. View

13.

McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A . Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014; 50(4):774-83. DOI: 10.1016/j.ejca.2013.12.013. View

14.

Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A . XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 2012; 59(120):2635-9. DOI: 10.5754/hge12181. View

15.

Endrizzi B, Ahmed R, Ray T, Dudek A, Lee P . Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg. 2013; 39(4):634-45. DOI: 10.1111/dsu.12049. View

16.

Leiter U, Eigentler T, Garbe C . Epidemiology of skin cancer. Adv Exp Med Biol. 2014; 810:120-40. DOI: 10.1007/978-1-4939-0437-2_7. View

17.

Salem P, Hall S, Benjamin R, Murphy W, Wharton J, Bodey G . Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion. Cancer Treat Rep. 1978; 62(10):1553-5. View